Article

Restoration of Microvascular Function in the Infarct-Related Artery by Intracoronary Transplantation of Bone Marrow Progenitor Cells in Patients With Acute Myocardial Infarction The Doppler Substudy of the Reinfusion of Enriched Progenitor Cells and Infarct Remodeling in Acute Myocardial Infarction (REPAIR-AMI) Trial

Ruhr-Universität Bochum, Bochum, North Rhine-Westphalia, Germany
Circulation (Impact Factor: 14.95). 08/2007; 116(4):366-74. DOI: 10.1161/CIRCULATIONAHA.106.671545
Source: PubMed

ABSTRACT The Doppler Substudy of the randomized, double-blind, placebo-controlled Reinfusion of Enriched Progenitor Cells and Infarct Remodeling in Acute Myocardial Infarction (REPAIR-AMI) trial aimed to investigate the effects of intracoronary infusion of bone marrow-derived progenitor cells (BMCs) on coronary blood flow regulation in patients with reperfused acute myocardial infarction.
In a total of 58 patients (BMC group, n=30; placebo group, n=28), coronary flow reserve (CFR) in the infarct artery and a reference vessel was assessed by intracoronary Doppler at the time of study therapy (4.2+/-0.1 days after acute myocardial infarction) and at the 4-month follow-up. Initial CFR was reduced in the infarct artery compared with the reference vessel in both groups (BMC: 2.0+/-0.1 versus 2.9+/-0.2, P<0.05; placebo: 1.9+/-0.1 versus 2.8+/-0.2; P<0.05). At the 4-month follow-up, CFR in the infarct artery had slightly improved in the placebo group (+0.88+/-0.18; P<0.001 versus initial) but was markedly increased by 90% (+1.80+/-0.25; P=0.005 versus placebo) in BMC-treated patients, resulting in a normalization of CFR (3.8+/-0.2; P<0.001 versus initial and placebo at 4 months). In the infarct vessel, adenosine-induced minimal vascular resistance index declined slightly in the placebo group (from 1.77+/-0.12 to 1.52+/-0.15 mm Hg x s/cm; P<0.05) but considerably decreased by -29+/-6% in the BMC group (from 1.86+/-0.19 to 1.20+/-0.12 mm Hg x s/cm; P<0.05 versus initial and placebo at 4 months).
Intracoronary BMC therapy after acute myocardial infarction restores microvascular function of the infarct-related artery, which is associated with a significant improvement in maximal vascular conductance capacity. These data provide clinical proof of concept that progenitor cell transplantation promotes vascular repair.

Download full-text

Full-text

Available from: Torsten Tonn, Jul 18, 2015
0 Followers
 · 
162 Views
  • Source
    • "Bone marrow–derived endothelial progenitor cells (EPCs) are responsible for neovascularization in postnatal life (Asahara et al. 1999; Takahashi et al. 1999). A large number of reports on EPCs have been accumulated as a potential tool in regenerative medicine (Schachinger et al. 2006a,b; Erbs et al. 2007; Martin- Rendon et al. 2008) or a therapeutic target in oncology (Gao et al. 2008). Although a unique EPC marker has not been identified, EPCs, which most investigators obtain after the in vitro culture, are characterized as cells with high proliferative potential that display typical endothelial characteristics [e.g., expression of endothelial markers and uptake of acetylated lowdensity lipoprotein (Ac-LDL)] and differentiate into ECs in vitro (Timmermans et al. 2009). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Nestin is an intermediate filament protein that is known as a neural stem/progenitor cell marker. It is expressed in undifferentiated central nervous system (CNS) cells during development, but also in normal adult CNS and in CNS tumor cells. Additionally, nestin is expressed in endothelial cells (ECs) of CNS tumor tissues and of adult tissues that replenish by angiogenesis. However, the regulation of nestin expression in vascular endothelium has not been analyzed in detail. This study showed that nestin expression was observed in proliferating endothelial progenitor cells (EPCs), but not in mature ECs. In adherent cultured cells derived from bone marrow cells, EPCs that highly expressed nestin also expressed the endothelial marker CD31 and the proliferation marker Ki67. ECs cultured without growth factors showed attenuated nestin immunoreactivity as they matured. Transgenic mice that carried the enhanced green fluorescent protein under the control of the CNS-specific second intronic enhancer of the nestin gene showed no reporter gene expression in EPCs. This indicated that the mechanisms of nestin gene expression were different in EPCs and CNS cells. Immunohistochemistry showed nestin expression in neovascular cells from two distinct murine models. Our results demonstrate that nestin can be used as a marker protein for neovascularization.
    Journal of Histochemistry and Cytochemistry 08/2010; 58(8):721-30. DOI:10.1369/jhc.2010.955609 · 2.40 Impact Factor
  • Source
    • "Indirect assessments can be obtained with conventional measurements of tissue perfusion, such as single-photon emission computed tomography (SPECT) or magnetic-resonance imaging (MRI), but the sensitivity of these techniques is limited. Nevertheless, in a substudy of the REPAIR-AMI (i.e., Reinfusion of Enriched Progenitor Cells and Infarct Remodeling in Acute Myocardial Infarction) trial, intracoronary Doppler measurements indicated that coronary flow reserve in the infarct-related artery was restored 4 months after the infusion of bone-marrow progenitor cells (Erbs et al., 2007), and in our phase 1/ IIa pilot study, positive trends in SPECT perfusion imaging were observed after CD34+ progenitor cells were injected into the hibernating myocardium of patients with chronic angina (Losordo et al., 2007). These trends are further substantiated by findings in our phase IIb ACT34-CMI trial (Losordo et al., 2009). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Cell-based therapy has emerged as a promising therapeutic tool for treatment of ischemic cardiovascular disease. Both unselected bone marrow-derived mononuclear cells (BMNCs), which include stem/progenitor cells and several other cell types, and endothelial progenitor cells (EPCs), a subpopulation of BMNCs, display regenerative potential in ischemic tissue. Abundant evidence supports the involvement of EPCs in capillary growth, and EPCs also appear to participate in the formation of collateral vessels. Collectively, these effects have led to improved perfusion and functional recovery in animal models of myocardial and peripheral ischemia, and in early clinical trials, the therapeutic administration of EPCs to patients with myocardial infarction or chronic angina has been associated with positive trends in perfusion. EPCs also contribute to endothelial repair and may, consequently, impede the development or progression of arteriosclerosis. This review provides a brief summary of the preclinical and clinical evidence for the role of EPCs in blood-vessel formation and repair during ischemic cardiovascular disease.
    Microvascular Research 02/2010; 79(3):200-6. DOI:10.1016/j.mvr.2010.01.012 · 2.43 Impact Factor
  • Source
    • "Intracoronary injection of autologous mononuclear bone marrow cells (mBMCs) in patients with acute myocardial infarction (AMI) induces a short-term inflammatory response, which declines after 3 months, as determined by the circulating levels of selected inflammatory markers, suggesting an appropriate window for stem cell transplantation in AMI (Solheim et al., 2008). Intracoronary infusion of bone marrow-derived progenitor cell (BMC) therapy after acute myocardial infarction significantly improves maximal vascular conductance capacity, indicating that implanted BMC promotes vascular repair (Erbs et al., 2007). To address concerns regarding the pro-arrhythmic potential of stem cells, Katritsis et al. (2007) Fig. 4 "
    [Show abstract] [Hide abstract]
    ABSTRACT: Heart disorders are a major health concern worldwide responsible for millions of deaths every year. Among the many disorders of the heart, myocardial infarction, which can lead to the development of congestive heart failure, arrhythmias, or even death, has the most severe social and economic ramifications. Lack of sufficient available donor hearts for heart transplantation, the only currently viable treatment for heart failure other than medical management options (ACE inhibition, beta blockade, use of AICDs, etc.) that improve the survival of patients with heart failure emphasises the need for alternative therapies. One promising alternative replaces cardiac muscle damaged by myocardial infarction with new contractile cardiomyocytes and vessels obtained through stem cell-based regeneration. We report on the state of the art of recovery of cardiac functions by using stem cell engineering. Current research focuses on (a) inducing stem cells into becoming cardiac cells before or after injection into a host, (b) growing replacement heart tissue in vitro, and (c) stimulating the proliferation of the post-mitotic cardiomyocytes in situ. The most promising treatment option for patients is the engineering of new heart tissue that can be implanted into damaged areas. Engineering of cardiac tissue currently employs the use of co-culture of stem cells with scaffold microenvironments engineered to improve tissue survival and enhance differentiation. Growth of heart tissue in vitro using scaffolds, soluble collagen, and cell sheets has unique advantages. To compensate for the loss of ventricular mass and contractility of the injured cardiomyocytes, different stem cell populations have been extensively studied as potential sources of new cells to ameliorate the injured myocardium and eventually restore cardiac function. Unresolved issues including insufficient cell generation survival, growth, and differentiation have led to mixed results in preclinical and clinical studies. Addressing these limitations should ensure the successful production of replacement heart tissue to benefit cardiac patients.
    Cell Biology International 03/2009; 33(3):255-67. DOI:10.1016/j.cellbi.2008.11.009 · 1.64 Impact Factor
Show more